[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"normal-pressure-hydrocephalus\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:normal-pressure-hydrocephalus":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,43,72,104,149,182,208,239],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100548823","addressing-health-disparities-in-normal-pressure-hydrocephalus-nph-in-maryland-100548823",false,"NCT06426004","Addressing Health Disparities in Normal Pressure Hydrocephalus (NPH) in Maryland","Community Interventions to Address Health Disparities in the Care of Normal Pressure Hydrocephalus (NPH) in Maryland","NPH","Inclusion Criteria:\n\n* People over 65 years old who have completed the Annual Wellness Survey (AWV) survey\n* have a clinical profile in the Hopkins Epic data sets\n* live in Maryland\n\nExclusion Criteria:\n\n* People under 65 years old will be excluded if they have not completed the AWV survey\n* do not live in Maryland\n\nCommunity Health Worker (CHW) Inclusion Criteria:\n\n* certified Community Health Workers from Maryland\n* completed accredited training by the Maryland Department of Health\n\nPrimary Care Physician inclusion criteria:\n\n* must have patients in Johns Hopkins University AWV",true,"ALL","65 Years",{"count":21,"type":22},660,"ESTIMATED","INTERVENTIONAL",[25],"NA","The study aims to estimate Normal Pressure Hydrocephalus (NPH) prevalence and evaluate health equity gaps in Baltimore and Maryland based on zip codes and race, with a focus on the Black community. Interventions will include educational elements about NPH and three layers targeting patients, Primary Care Providers, and community health workers to enhance care access. Short-term outcomes will measure referrals to specialists, while long-term outcomes will assess healthcare utilization. The study aims to identify and reduce racial disparities in NPH care access, informing intervention strategies for NPH and other surgical areas.",[28,29],"Normal Pressure Hydrocephalus","Hakim Syndrome","NOT_YET_RECRUITING","2026-05-01",{"date":33,"type":34},"2026-05-07","ACTUAL",{"date":36,"type":22},"2027-08-01",{"date":38,"type":22},"2032-03-30",{"name":40,"class":41},"Johns Hopkins Bloomberg School of Public Health","OTHER",2,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":17,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":71},"100509247","european-study-of-prodromal-inph-100509247","NCT05910944","European Study of Prodromal iNPH","STOP iNPH","Inclusion criteria - Group 1 - prodromal iNPH\n\n* Brain imaging with both:\n\n  * Evans index \\> 0.3\n  * Callosal angle ≤ 90 º or:\n  * Disproportionately enlarged subarachnoid space hydrocephalus (DESH) - defined as: enlarged ventricles, dilated sylvian fissures and tight sulci at the high convexity.\n* Absence of symptoms or too mild symptoms to motivate shunt surgery according to local routine, and all of the following:\n\n  * Normal gait pattern, or slight disturbance of the gait pattern that is not considered to be caused by a disease in the central nervous system (CNS).\n  * Gait velocity (maximum gait speed), men ≥ 1.4 m\u002Fs; women ≥ 1.25 m\u002Fs.\n  * Rombergs test with eyes open \\> 60 seconds\n  * Mini Mental State Examination (MMSE) ≥ 27 or Montreal Cognitive Assessment (MoCA) ≥ 23\n* Informed consent\n\nExclusion criteria - Group 1 - prodromal iNPH\n\n* Contraindication for MRI\n* Other serious disease with expected survival less than three years\n* Other type of hydrocephalus:\n\n  * non-communicating hydrocephalus\n  * secondary communicating hydrocephalus\n  * suspected congenital hydrocephalus (severely enlarged ventricles, narrow sylvian fissures and normal non-compressed sulci at the high convexity or morphological findings consistent with PaVM18)\n* Anticoagulants in a dose that hinders lumbar puncture\n\nInclusion criteria - Group 2 - healthy controls\n\n• Age \\> 65 years\n\nExclusion criteria - Group 2 - healthy controls:\n\n* Imaging findings meet inclusion criteria of Group 1\n* Previously known relevant neurological disease\n* Pathological gait pattern with unknown reason.\n* MMSE \\\u003C 27 or MoCA \\\u003C 26.\n* Anticoagulants in a dose that hinders lumbar puncture\n\nInclusion criteria Group 3 symptomatic iNPH\n\n* iNPH diagnosis according to international guidelines.19\n* Age matched with the individual in Group 1 (+\u002F- 3 years)\n\nExclusion criteria Group 3 symptomatic iNPH\n\n* Previous stroke (clinical stroke, not only radiologically verified)\n* Other serious disease with expected survival less than three years",{"count":51,"type":22},140,"OBSERVATIONAL","To investigate if progression from prodromal into symptomatic NPH can be predicted from advanced neuroimaging, biomarkers in cerebrospinal fluid (CSF) and plasma and investigate the unknown mechanisms causing deterioration by investigating longitudinal changes in the above-mentioned variables. Three different cohorts with both asymptomatic and symptomatic patients as well as healthy controls will be investigated over time, both without intervention and before and after shunt surgery.",[28,55],"Hydrocephalus",[57,58,59,60],"natural history","cerebrospinal fluid","biomarkers","long term follow-up","RECRUITING","2026-04-29",{"date":64,"type":34},"2026-04-30",{"date":66,"type":34},"2023-11-01",{"date":68,"type":22},"2035-12-31",{"name":70,"class":41},"Johan Virhammar",7,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":18,"minAge":80,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":23,"phases":83,"briefSummary":84,"conditions":85,"keywords":88,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":103},"100398714","normal-pressure-hydrocephalus-and-sleep-apnea-100398714","NCT04471740","Normal Pressure Hydrocephalus and Sleep Apnea","Normal-pressure Hydrocephalus. Relationship Between Sleep Apnea and Intracranial and Intraabdominal Pressures. Outcome Prognostic Factors in CSF Shunting. Features Guiding to Implant a Ventricle-peritoneal Versus a Ventriculo-atrial Shunt","NPH\u002FOSA","Inclusion Criteria:\n\n* Clinical condition compatible with normal-pressure hydrocephalus\n\nExclusion Criteria:\n\n* Cerebral vascular disease\n* Dementia not due to normal-pressure hydrocephalus\n* Parkinson's disease","18 Years",{"count":82,"type":22},30,[25],"Normal-pressure hydrocephalus is associated with increases in the intracranial pressure during the night sleep. Sleep apnea also increases the intracranial pressure during the apneic spells. When patients are operated the distal part of the shunt is inserted inside the abdominal cavity, which pressure also increases during the sleep apnea episodes. this is particularly important considering that the recumbent position used to sleep further increases the intraabdominal pressure and that impairs the CSF drainage through the shunt system. The purpose of this study is to analyze the intracranial and intraabdominal pressures during the sleep, particularly during the sleep apnea episodes to see which shunt should be used, to which cavity should be drained (peritoneum or heart) and if correcting the sleep apnea has some positive result on the hydrocephalus symptoms.",[28,86,87],"Sleep Apnea","Cerebrospinal Fluid Shunt Occlusion",[89,90,91,92,93],"Normal pressure hydrocephalus","Sleep apnea","CSF shunt diversion","Ventriculo-peritoneal shunt","Ventriculo-atrial shunt","2026-04-18",{"date":96,"type":34},"2026-04-22",{"date":98,"type":34},"2020-07-02",{"date":100,"type":22},"2029-12",{"name":102,"class":41},"University of Valencia",1,{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":18,"minAge":80,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":114,"conditions":115,"keywords":137,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":148},"100571728","neurosurgical-outcome-network-100571728","NCT06724029","Neurosurgical Outcome Network","Neurosurgical Outcome Network Per la Predizione Dell'Outcome in Neurochirurgia","NEON","Inclusion Criteria:\n\n* Neuro-oncological pathology: supratentorial and subtentorial tumors, intra and extra axial tumors excluding the skull base (anterior, middle and posterior fossa; sellar and parasellar region)\n* Basicranial pathology: tumors originating from the anterior cranial fossa, middle cranial fossa and posterior cranial fossa, sellar region with or without supratentorial\u002Fparasellar development.\n* Vascular pathology: aneurysms, AVMs, cavernomas, other pathologies (Moyamoya disease, dural fistulas, nontraumatic hematomas)\n* Traumatic pathology: diffuse damage (nonvisible diffuse damage, diffuse damage, diffuse damage with edema, diffuse damage with shift) and focal damage (acute\u002Fsubacute\u002Fchronic subdural hematoma, extradural hematoma, subarachnoid hemorrhage, intraparenchymal hematoma, fractures); hydrocephalus. The inclusion criterion for chronic subdural hematoma is recent bleeding for TBI with CT finding of chronic subdural hematoma candidate for evacuation surgery.\n* Spinal pathology: degenerative cervical (anterior\u002Fposterior), myelopathic, and trauma pathology; instrumented, uninstrumented thoracolumbar pathology (disc pathology, canal pathology), and trauma pathology; oncologic spinal pathology.\n* Functional pathology: Parkinson's disease, spasticity, trigeminal neuralgia, craniofacial pain\u002Falgia, neuropathic pain, tremor, dystonias, obsessive compulsive disorder, drug-resistant epilepsies, depression. Normotensive hydrocephalus.\n* Peripheral nervous system pathology: peripheral nerve compression syndromes, peripheral nerve and plexus tumors, brachial plexus and peripheral nerve trauma (contusion and section)\n* Malformative pathology: Chiari malformation type 1 and craniostenoses including both those framed in malformative syndromes and those not framed in malformative syndromes (monosutural craniostenoses: trigonocephaly, plagiocephaly, scaphocephaly; multisutural craniostenoses). Malformative hydrocephalus.\n* For cognitive and psychological assessment: age 18 years or older; adequate understanding of Italian language; diagnosis of glioma, meningioma, vascular pathology, spinal pathology\n\nExclusion Criteria:\n\n* For cognitive and psychological assessment: patients with psychiatric diseases in history and\u002For taking psychotropic drugs; presence of overt cognitive decline (not due to the injury) in history; patients younger than 18 years old.",{"count":113,"type":22},4500,"The evaluation of neurosurgical outcomes varies from center to center, and the predictive factors that determine these outcomes are not fully known or shared. This study aims to assess outcomes and their predictors using measures agreed upon by the participating centers. Standardizing the evaluation of outcomes and predictors improves the quality of research, allows for data comparison, and facilitates a \"common language\" in routine clinical practice. Most importantly, it influences therapeutic decisions in various neurosurgical conditions. Clinically, the identified predictors can also be used during preoperative assessments to provide more precise guidance to patients undergoing surgery.",[116,117,118,119,120,121,122,123,124,55,125,126,127,128,129,130,131,132,133,134,28,135,136],"Aneurysms","Arteriovenous Malformations","Cavernomas","Skull Base Tumors","Moyamoya Disease","Dural Fistulas","Subdural Hematoma","Extradural Hematoma","Subarachnoid Hemorrhage","Parkinson&Amp;#39;s Disease","Spasticity","Trigeminal Neuralgia","Craniofacial Pain","Neuropathic Pain","Tremor","Dystonias","Obsessive-compulsive Disorder","Drug-resistant Epilepsy","Depression","Tumors of Peripheral Nerves","Chiari Malformation Type 1",[138],"Neurosurgery Outcome Artificial Intelligence predictors","2026-03-25",{"date":141,"type":34},"2026-03-30",{"date":143,"type":34},"2022-12-05",{"date":145,"type":22},"2027-06",{"name":147,"class":41},"Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta",27,{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":155,"eligibilityCriteria":156,"healthyVolunteers":17,"sex":18,"minAge":157,"maxAge":4,"enrollmentInfo":158,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":160,"conditions":161,"keywords":162,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":103},"100600914","white-matter-distortion-and-dementia-biomarkers-in-normal-pressure-hydrocephalus-nph-100600914","NCT07103681","White Matter Distortion and Dementia Biomarkers in Normal Pressure Hydrocephalus (NPH)","Observational Study to Investigate the Effect of White Matter Tract Distortion and Neurodegenerative Biomarkers on Shunt-responsiveness in Idiopathic Normal Pressure Hydrocephalus (iNPH)","OWN-NPH","Group 1 (communicating hydrocephalus):\n\nInclusion Criteria:\n\n* Adult patients \\>60\n* With gait apraxia\n* With or without cognitive impairment\n* Urinary dysfunction\n* Communicating Hydrocephalus\n\nExclusion Criteria:\n\n* Asymptomatic hydrocephalus\n* High pressure-hydrocephalus\n* Serious head injury within 5 years of presentation or a clear secondary cause (e.g. brain infection)\n* History of childhood gait disturbance\n* Clear alternative explanation for symptoms (e.g. Parkinson's disease with limb rigidity, peripheral neuropathy with sensory ataxia, cervical myelopathy).\n* Too frail for shunt surgery\n* Medically unstable (e.g. active angina, respiratory disease, recurrent delirium, active epilepsy).\n* Unable to tolerate MRI brain imaging\n* Unable to have a lumbar puncture\n* Immobile\n* Unable to attend the hospital for study visits\n\nGroup 2 (asymptomatic and non-hydrocepahlus dementia and healthy controls):\n\nInclusion Criteria (Any of the following):\n\n* Healthy Carers\n* Members of the Public\n* Staff of Imperial College\u002FICHT\n* Non-NPH Dementias (including Alzheimer's disease or vascular dementia)\n* Asymptomatic Hydrocephalus\n\nExclusion Criteria:\n\n\\- Unable to attend the hospital for study visits","60 Years",{"count":159,"type":22},100,"Idiopathic Normal Pressure Hydrocephalus (iNPH) is a progressive condition of the elderly that results in severe disability. iNPH can dramatically respond to Cerebral spinal fluid(CSF)-shunting where excess ventricular fluid is diverted from the brain. Not all patients with iNPH respond to CSF-shunting however. The reasons for this are uncertain.\n\nAim 1: To understand if specific nerve pathways (white matter tracts) that are near ventricles are damaged in patients that respond to shunting as opposed to those that do not.\n\nAim 2: Can we explain shunt non-responsiveness by screening for dementia like illnesses (neurodegeneration) using a large array of methods.\n\nAim 3: To understand whether wearable activity and bed sleep monitors are palatable in a NPH population and to understand if these metrics relate to quality of life.\n\nAim 4: To see whether self-administered digital cognitive assessments can measure improvements pre and post surgery.",[28],[163,164,165,166,167,168,169,170,171,172,15],"hydrocephalus","activity monitors","gait impairment","shunt surgery","protokinetic","normal pressure hydrocephalus","shunt-responsiveness","white matter tractography","diffusion tensor imaging","neurodegenerative","2026-03-24",{"date":175,"type":34},"2026-03-27",{"date":177,"type":34},"2025-03-25",{"date":179,"type":22},"2029-02",{"name":181,"class":41},"Imperial College London",{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":4,"eligibilityCriteria":188,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":189,"targetDuration":4,"studyType":23,"phases":191,"briefSummary":192,"conditions":193,"keywords":195,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":204,"leadSponsor":206,"locationsCount":4},"100606229","non-invasive-diagnostics-of-shunt-obstruction-in-adult-hydrocephalus-100606229","NCT07172841","Non-invasive Diagnostics of Shunt Obstruction in Adult Hydrocephalus","Randomized Controlled Study on Non-invasive Diagnostics of Shunt Obstruction in Adult Hydrocephalus","Inclusion Criteria:\n\n* Patients with normal pressure hydrocephalus (NPH)\n* Treated at either the Hydrocephalus Research Unit in Gothenburg or at the Department of Neurological Surgery at Linköping University Hospital or Sahlgrenska University Hospital\n\nExclusion Criteria:\n\n* Unable to conform to instructions of the study",{"count":190,"type":22},60,[25],"The goal of this RCT is to test whether volumetric assessment of magnetic resonance imaging (MRI) could diagnose shunt obstruction in Adult Hydrocephalus patients, and in addition to explore correlations of blood biomarkers surrounding shunt obstruction. Thirdly to investigate correlations with clinical symptom burden before and after surgery.\n\nThe main questions it aims to answer are:\n\nCan volumetric assessment of cerebrospinal fluid (CSF) aid in diagnosis of shunt obstruction? Are there dynamical changes in blood biomarker concentrations after shunt obstruction? How are clinical symptom burden and dynamics correlated with blood biomarker changes and volumetric changes in CSF?\n\nAfter three months of shunt treatment, researchers will compare patients with \"Virtual OFF\" setting, to explore if simulated shunt obstruction affect measures mentioned above.\n\nParticipants randomized to the intervention group will undergo the 'Virtual OFF' setting for a period of 5-7 days, starting 3 months after initiation of shunt treatment. Symptom burden will be assessed preoperatively, at follow-up, and following the week of the shunt setting change. MRI scans will be conducted at these same time points. Participants in the control group will also meet with a nurse, but their shunt settings will remain unchanged. The control group will receive the same symptom assessments and MRI scans as the intervention group.",[194,28],"Normal Pressure Hydrocephalus Patients",[196,197,198,15,199],"Volumetry","Shunt obstruction","Shunt patency","Outcome","2025-09-08",{"date":202,"type":34},"2025-09-15",{"date":202,"type":22},{"date":205,"type":22},"2034-12-31",{"name":207,"class":41},"Göteborg University",{"id":209,"slug":210,"hasResults":11,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":4,"eligibilityCriteria":214,"healthyVolunteers":17,"sex":18,"minAge":215,"maxAge":4,"enrollmentInfo":216,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":218,"conditions":219,"keywords":225,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":103},"100556734","proteinopathies-expression-in-skin-of-neurodegenerative-disorders-100556734","NCT06528964","Proteinopathies Expression in Skin of Neurodegenerative Disorders","Expression of Proteinopathies in Skin Biopsies of Patients With Neurodegenerative Disorders","Inclusion Criteria for patients:\n\n* Patients 45 years and older\n* Men and women\n* Patients diagnosed with Alzheimer's disease, frontotemporal lobe dementia, Parkinson's disease, atypical Parkinsonism, amyotrophic lateral sclerosis or normal pressure hydrocephalus\n* Patients that voluntarily accept to participate in the study and accept the consent form\n\nInclusion Criteria healthy control subjects:\n\n* People 45 years and older\n* Men and women\n* Subjects can be related to a patient but not by blood (for example spouse of a patient)\n* Subjects don't have direct family history of a neurodegenerative control\n* Subjects don't have any clinical findings suggesting dementia\n* Subjects voluntarily accept to participate in the study and accept the consent form\n\nExclusion Criteria:\n\n* Patients or controls that have a personal history of cerebrovascular disease, psychiatric disease, post traumatic dementia or HIV related dementia\n* Patients in which the diagnosis is not clear or hasn't been confirmed\n* Patients or controls that have a neuroinfection\n* Patients or controls that a diagnosed skin disease\n* Patients that have an \"atypical\" presentation of the disease\n* Patients or controls that have diagnosis of a coagulopathy","45 Years",{"count":217,"type":22},40,"The goal of this observational study is to compare the aggregation pattern of proteinopathies (alpha-synuclein, amyloid-beta, phosphorylated tau and transactive response DNA -binding protein 43 \\[TDP43\\]) in skin biopsies of patients with a neurodegenerative disease like Alzheimer's disease, frontotemporal lobe dementia, Parkinson's disease, atypical Parkinsonism, amyotrophic lateral sclerosis or normal pressure hydrocephalus. The main question it aims to answer is:\n\n* Is there a specific pattern of aggregation of proteinopathies in skin biopsies in each neurodegenerative disease in comparison to healthy control subjects?\n\nSkin biopsies will be analyzed using immunohistochemistry and immunofluorescence for detection of alpha-synuclein, amyloid-beta, phosphorylated tau and TAR DNA binding protein 43, and the aggregation patterns will be compared between patients with a neurodegenerative disease vs patient with normal pressure hydrocephalus vs healthy control subjects.",[220,221,222,223,224,28],"Alzheimer Disease","Frontotemporal Dementia","Parkinson Disease","Atypical Parkinsonism","Amyotrophic Lateral Sclerosis",[226,227,228,229],"Alpha Synuclein Pathology","Tauopathies","TDP-43 Proteinopathies","Beta-Amyloid","2024-12-13",{"date":232,"type":34},"2024-12-16",{"date":234,"type":34},"2023-12-20",{"date":236,"type":22},"2026-11-01",{"name":238,"class":41},"Universidad Autonoma de San Luis Potosí",{"id":240,"slug":241,"hasResults":11,"nctId":242,"briefTitle":243,"officialTitle":244,"acronym":4,"eligibilityCriteria":245,"healthyVolunteers":11,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":246,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":248,"conditions":249,"keywords":250,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":261,"locationsCount":103},"100571631","identifying-gait-changes-from-a-csf-tap-test-using-a-smart-insole-in-inph-100571631","NCT06722768","Identifying Gait Changes From a CSF Tap Test Using a Smart Insole in iNPH","Identifying Gait Changes From a Cerebrospinal Fluid Tap Test Using a Smart Insole in Idiopathic Normal Pressure Hydrocephalus","Inclusion Criteria:\n\n* individuals who have more than 1 symptom in the clinical triad including gradually developed gait disturbances mainly showing shuffling, magnetic, wide based gait\n* individuals who assessed a standardized cranial MRI scan and those with an Evans ratio greater than 0.30 were included in the study (Microvascular lesions in the white matter were accepted only if they were mild.)\n* individuals who voluntarily agree to participate in the study and sign a consent form\n\nExclusion Criteria:\n\n* individuals with history of hemorrhage\n* individuals unable to walk independently on flat ground for 10 meters\n* individuals with clinically significant disorders in the cardiovascular, gastrointestinal, respiratory, or endocrine systems\n* individuals considered clinically unsuitable for the trial by the trial manager or person in charge based on significant medical findings",{"count":247,"type":22},50,"The goal of this clinical trial is to to evaluate various gait parameters by a sensor-embedded smart insole before and after the cerebrospinal fluid (CSF) tap test in idiopathic normal pressure hydrocephalus (iNPH) patients.\n\nThe main questions it aims to answer are:\n\n* Does the CSF tap test enhance gait and balance parameters in participants?\n* Does the CSF tap test enhance cognitive and urinary symptoms in participants?\n\nResearchers will compare pre- and post-CSF tap test gait and balance parameters by a sensor-embedded smart insole.\n\nParticipants will:\n\n* Participate in physical function assessments including the 10-meter walk test, Timed Up and Go test, and Berg Balance Scale wearing sensor-embedded smart insoles before and after the CSF tap test.\n* Complete survey about cognitive and unary symptoms before and after the CSF tap test.",[28],[251,252,253],"gait analysis","smart insole","Cerebrospinal fluid tap test","2024-12-03",{"date":256,"type":34},"2024-12-09",{"date":258,"type":34},"2021-06-01",{"date":260,"type":22},"2025-02",{"name":262,"class":41},"Yonsei University"]